Erratum to: Diagnosis and treatment of adult-onset Still’s disease: a concise summary of the German society of rheumatology S2 guideline

Erratum to:

Z Rheumatol 2022

https://doi.org/10.1007/s00393-022-01294-2

In the original version of the article, there is unfortunately an error in the legend to Fig. 2.

Please refer to the corrected version:

Fig. 2

Treatment of adult-onset Still’s disease (AOSD; Level of evidence (LoE) 5—expert opinion). After determination of disease activity, treatment is usually commenced with glucocorticoids (¹Licensed for active disease states of rheumatic diseases). Methotrexate (MTX) or calcineurin inhibitors (CNI), in case of higher disease activity, additionally anakinra, canakinumab, or tocilizumab, are introduced as glucocorticoid-sparing agents. *In case of a non-response to MTX/CNI, anakinra, canakinumab, or tocilizumab should subsequentially be used even in cases of lower disease activity states. Nonsteroidal anti-inflammatory drugs (NSAIDs; ²licensed for pain and fever) can be used temporarily for symptom control. Anakinra and canakinumab can be used as a first-line option in case of severe disease activity (³licensed in case of non-response to glucocorticoids and NSAIDs; in the case of anakinra, additionally in case of moderate to high disease activity even before glucocorticoids and NSAIDs). GoR grade of recommendation, LoE level of evidence, LoE 5 expert opinion; 100% consensus was obtained for the treatment algorithm

We apologize for our oversight.

The editorial office